Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist
Author(s) -
John A. Zebala,
Aaron D. Schuler,
Stuart J. Kahn,
Dean Y. Maeda
Publication year - 2020
Publication title -
frontiers in pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.384
H-Index - 86
ISSN - 1663-9812
DOI - 10.3389/fphar.2019.01680
Subject(s) - morphine , opioid , oxycodone , fentanyl , pharmacology , tramadol , medicine , agonist , opioid receptor , anesthesia , receptor , analgesic
Tramadol is widely used globally and is the second most prescribed opioid in the United States. It treats moderate to severe pain but lethal opioid-induced respiratory depression is uncommon even in large overdose. It is unknown why tramadol spares respiration. Here we show its active metabolite, desmetramadol, is as effective as morphine, oxycodone and fentanyl in eliciting G protein coupling at the human µ opioid receptor (MOR), but surprisingly, supratherapeutic concentrations spare human MOR-mediated βarrestin2 recruitment thought to mediate lethal opioid-induced respiratory depression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom